Pharmafile
Is the Current EU Legal Framework for Orphan Medicines Fit for Purpose?
Autumn 2019
Maria Isabel Manley, partner and head of the UK Global Life Sciences Practice, and Chris Boyle, associate, at Sidley, discuss the impact of regulatory frameworks on medicines for rare diseases.
Contacts
Capabilities
Suggested News & Insights
Growth Meets Guardrails: Getting You Ready for the New Realm of Ad/PromoWednesday, May 13, 2026Sidley Represents MacroGenics in the Sale of Its GMP Manufacturing OperationsMay 11, 2026Sidley Represents Underwriters in Connection With Pharvaris’ US$115 Million Underwritten Offering of Ordinary SharesMay 8, 2026Sidley Represents Archimed in US$1.1 Billion Acquisition of Esperion TherapeuticsMay 1, 2026Most-Favored-Nation Drug Pricing Policy: Executive Actions, Manufacturer Agreements, and Growing Congressional ScrutinyApril 22, 2026Sidley Represents Opus Genetics in US$155 Million Financing With Oberland CapitalApril 21, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory